{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:18:49Z","timestamp":1794136729246,"version":"4.8.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["182102311233"],"award-info":[{"award-number":["182102311233"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105076","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:51:39Z","timestamp":1765299099000},"page":"105076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Harnessing the effector-to-regulatory T cell ratio to advance prognosis and precision therapy in pancreatic cancer"],"prefix":"10.1016","volume":"218","author":[{"given":"Xuejun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9228-6162","authenticated-orcid":false,"given":"Wenxue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105076_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.105076_bib2","first-page":"18871","article-title":"Knockdown of TBRG4 suppresses the migration, invasion, and epithelial-to-mesenchymal transition of pancreatic cancer cells via TGF-beta\/smad3 signaling","author":"Ye","year":"2025","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101129","article-title":"Informatics strategies for early detection and risk mitigation in pancreatic cancer patients","volume":"60","author":"Jin","year":"2025","journal-title":"Neoplasia"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105076_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179555","article-title":"The role of tumor microenvironment in pancreatic cancer immunotherapy: current status and future perspectives","volume":"25","author":"Poyia","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105076_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216345","article-title":"Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers","volume":"571","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-025-02265-2","article-title":"Cancer stem cells and niches: challenges in immunotherapy resistance","volume":"24","author":"Pan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105076_bib7","article-title":"Targeting tumor-infiltrating tregs for improved antitumor responses","volume":"15","author":"Qin","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib9","doi-asserted-by":"crossref","DOI":"10.4110\/in.2025.25.e13","article-title":"Regulatory T cell metabolism: a promising therapeutic target for cancer treatment?","volume":"25","author":"Kim","year":"2025","journal-title":"Immune Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib10","article-title":"Targets of tumor microenvironment for potential drug development","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105076_bib11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-022-05351-1","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008898","article-title":"TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion","volume":"12","author":"Debesset","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib13","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.critrevonc.2025.105076_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.intimp.2017.04.003","article-title":"IFNgamma enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells","volume":"47","author":"Shao","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.570003","article-title":"Novel survivin peptides screened with computer algorithm induce cytotoxic T lymphocytes with higher cytotoxic efficiency to cancer cells","volume":"7","author":"Chen","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/imm.12783","article-title":"Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses","volume":"152","author":"Li","year":"2017","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-024-05134-6","article-title":"CD8(+) T cell-based cancer immunotherapy","volume":"22","author":"Chen","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105076_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13195028","article-title":"Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches","volume":"13","author":"Truong","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106628","article-title":"Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors","volume":"85","author":"Yao","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117590","article-title":"Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: implications for cancer therapy","volume":"180","author":"Qi","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105076_bib23","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-24-2447","article-title":"Nutrient levels and nutrient sources in pancreatic tumors","volume":"84","author":"Groessl","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/imm.13871","article-title":"Metabolic reprogramming in cancer: implications for immunosuppressive microenvironment","volume":"174","author":"Aden","year":"2025","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105076_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bbmt.2010.08.005","article-title":"CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells","volume":"17","author":"Zhou","year":"2011","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105076_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137346","article-title":"Complex role of regulatory T cells (Tregs) in the tumor microenvironment: their molecular mechanisms and bidirectional effects on cancer progression","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41423-021-00742-4","article-title":"Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy","volume":"19","author":"Huppert","year":"2022","journal-title":"Cell Mol. Immunol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105076_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137171","article-title":"Regulatory T cell dysfunction in autoimmune diseases","volume":"25","author":"Honing","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105076_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457189","article-title":"Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations","volume":"15","author":"Ge","year":"2024","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105076_bib30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","article-title":"Intricacies of TGF-beta signaling in Treg and Th17 cell biology","volume":"20","author":"Wang","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295684","article-title":"Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs","volume":"14","author":"Shao","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","article-title":"Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105076_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814114","article-title":"The role of regulatory T cells in cancer treatment resistance","volume":"24","author":"Dabrowska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105076_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194582","article-title":"Regulatory T cells in pancreatic cancer: of mice and men","volume":"14","author":"Mota Reyes","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008898","article-title":"TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion","volume":"12","author":"Debesset","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105076_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113952","article-title":"Unleashing the power of immune checkpoints: a new strategy for enhancing treg cells depletion to boost antitumor immunity","volume":"147","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1242909","article-title":"Unveiling the role of regulatory T cells in the tumor microenvironment of pancreatic cancer through single-cell transcriptomics and in vitro experiments","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.717421","article-title":"Lineage reprogramming of effector regulatory T cells in cancer","volume":"12","author":"Dixon","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41698-025-00848-2","article-title":"Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes","volume":"9","author":"Zhang","year":"2025","journal-title":"NPJ Precis Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105076_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132438","article-title":"Decoding the intricate landscape of pancreatic cancer: insights into tumor biology, microenvironment, and therapeutic interventions","volume":"16","author":"Argentiero","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1535-7163.MCT-24-0311","article-title":"Looking beyond checkpoint inhibitor monotherapy: uncovering new frontiers for pancreatic cancer immunotherapy","volume":"24","author":"Giurini","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib45","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-025-56002-w","article-title":"Increased SOAT2 expression in aged regulatory T cells is associated with altered cholesterol metabolism and reduced anti-tumor immunity","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105076_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218109","article-title":"Harnessing IL-2 without feeding the enemy: modern strategies to overcome regulatory T cell expansion in cancer immunotherapy","volume":"635","author":"Ma","year":"2025","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105076_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082274","article-title":"Mechanisms of T-cell exhaustion in pancreatic cancer","volume":"12","author":"Saka","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115432","article-title":"The tumor microenvironment is an ecosystem sustained by metabolic interactions","volume":"44","author":"Kay","year":"2025","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105076_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105076_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105076_bib57","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1021\/acsptsci.4c00156","article-title":"Deciphering regulatory T-cell dynamics in cancer immunotherapy: mechanisms, implications, and therapeutic innovations","volume":"7","author":"Bhattacharya","year":"2024","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.critrevonc.2025.105076_bib58","article-title":"The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"32","key":"10.1016\/j.critrevonc.2025.105076_bib59","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200879119","article-title":"An anti-CTLA-4 heavy chain-only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile","volume":"119","author":"Gan","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105076_bib60","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/imm.13337","article-title":"CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function","volume":"163","author":"Whiteside","year":"2021","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s12967-024-05518-8","article-title":"Targeting tumor-infiltrating CCR8(+) regulatory T cells induces antitumor immunity through functional restoration of CD4(+) T(convs) and CD8(+) T cells in colorectal cancer","volume":"22","author":"Chen","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13046-025-03286-x","article-title":"CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype","volume":"44","author":"Tian","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105076_bib63","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4049\/jimmunol.2300067","article-title":"Immunotherapy targeting CCR8+ regulatory T cells induces antitumor effects via dramatic changes to the intratumor CD8+ T cell profile","volume":"211","author":"Ueyama","year":"2023","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib64","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/0008-5472.CAN-20-3585","article-title":"Fc-optimized anti-CCR8 antibody depletes regulatory t cells in human tumor models","volume":"81","author":"Campbell","year":"2021","journal-title":"Cancer Res"},{"issue":"50","key":"10.1016\/j.critrevonc.2025.105076_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba5264","article-title":"An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice","volume":"5","author":"Khoryati","year":"2020","journal-title":"Sci. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib66","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.it.2023.09.003","article-title":"IL-2-driven CD8(+) T cell phenotypes: implications for immunotherapy","volume":"44","author":"Niederlova","year":"2023","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105076_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173107","article-title":"A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models","volume":"134","author":"Efe","year":"2024","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib68","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2452654","article-title":"Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy","volume":"14","author":"Tanigawa","year":"2025","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105076_bib69","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","article-title":"IL2 targeted to CD8+ T cells promotes robust effector T-cell responses and potent antitumor immunity","volume":"14","author":"Moynihan","year":"2024","journal-title":"Cancer Discov."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105076_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163862","article-title":"A paradoxical role for regulatory T cells in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Brouwer","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105076_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105076_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509956","article-title":"From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases","volume":"15","author":"Bulliard","year":"2024","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105076_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: advancing clinical applications in cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib74","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","article-title":"Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy","volume":"18","author":"Hu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1635771","article-title":"Cancer-associated fibroblasts: dual roles from senescence sentinels to death regulators and new dimensions in therapy","volume":"16","author":"Ruan","year":"2025","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","article-title":"Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects","volume":"32","author":"Cao","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib78","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1186\/s12967-025-07244-1","article-title":"Immunometabolic reprogramming in lung cancer: interplay between immune and stem-like cells in immune checkpoint inhibitor resistance","volume":"23","author":"Sung","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib79","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1186\/s12967-025-07272-x","article-title":"Lactate at the crossroads of tumor metabolism and immune escape: a new frontier in cancer therapy","volume":"23","author":"Dong","year":"2025","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105076_bib80","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.21037\/jgo-24-560","article-title":"LDHA as a predictive biomarker and its association with the infiltration of immune cells in pancreatic adenocarcinoma","volume":"15","author":"Zheng","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib81","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10238-024-01362-8","article-title":"Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody","volume":"24","author":"Roider","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105076_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202414931","article-title":"Reshape the fates of Treg and CD8+T Cells Through IL-2Ralpha by synergizing divergent receptor-biased IL-2 PEGylates","volume":"12","author":"Sun","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2025.105076_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1406250","article-title":"Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?","volume":"15","author":"Smith","year":"2024","journal-title":"Front Immunol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105076_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164235","article-title":"Challenges and future perspectives of immunotherapy in pancreatic cancer","volume":"13","author":"Wandmacher","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib85","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2426305","article-title":"SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity","volume":"25","author":"Zhang","year":"2024","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib86","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1016\/j.ymthe.2024.09.010","article-title":"A CD25xTIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion","volume":"32","author":"Wei","year":"2024","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib87","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/s41467-021-27574-0","article-title":"Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab","volume":"12","author":"Maeda","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.105076_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117430","article-title":"Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer","volume":"179","author":"Ni","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105076_bib89","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semcancer.2022.12.003","article-title":"Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines","volume":"88","author":"Oladejo","year":"2023","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib90","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-beta and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib91","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41467-023-40398-4","article-title":"Combined PD-L1\/TGFbeta blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors","volume":"14","author":"Castiglioni","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib92","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008594","article-title":"Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8(+) T cells","volume":"13","author":"Shin","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105076_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: A promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105076_bib95","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.1158\/1078-0432.CCR-17-0831","article-title":"4-1BB agonist focuses CD8(+) Tumor-Infiltrating T-cell growth into a distinct repertoire capable of tumor recognition in pancreatic cancer","volume":"23","author":"Sakellariou-Thompson","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib96","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10555-021-09981-3","article-title":"Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance","volume":"40","author":"Heumann","year":"2021","journal-title":"Cancer Metastas.. Rev."},{"key":"10.1016\/j.critrevonc.2025.105076_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176451","article-title":"A new era of immune therapeutics for pancreatic cancer: monoclonal antibodies paving the way","volume":"969","author":"Balar","year":"2024","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-092733","article-title":"Protocol for a first-in-human feasibility study of T regulatory cells (TR004) for inflammatory bowel disease using (ex vivo) Treg expansion (TRIBUTE)","volume":"15","author":"Rodger","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.critrevonc.2025.105076_bib99","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2023.12.053","article-title":"Recent advances in drug delivery and targeting for the treatment of pancreatic cancer","volume":"366","author":"Pramanik","year":"2024","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib100","doi-asserted-by":"crossref","DOI":"10.1200\/OA-24-00050","article-title":"Challenges and opportunities in targeting the complex pancreatic tumor microenvironment","author":"Finan","year":"2024","journal-title":"JCO Oncol. Adv."},{"key":"10.1016\/j.critrevonc.2025.105076_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217662","article-title":"Pancreatic cancer precursor lesions - Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?","volume":"619","author":"Enzler","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib102","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib103","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib104","article-title":"Chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105076_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12091979","article-title":"The road ahead in pancreatic cancer: emerging trends and therapeutic prospects","volume":"12","author":"Do","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib106","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41392-024-02052-3","article-title":"Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105076_bib107","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00535-024-02197-6","article-title":"An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum","volume":"60","author":"Devasahayam Arokia Balaya","year":"2025","journal-title":"J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64053-0","article-title":"KPC-luciferase-expressing cells elicit an anti-tumor immune response in a mouse model of pancreatic cancer","volume":"14","author":"Ferrari","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105076_bib109","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00092","article-title":"Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","author":"Quintanilha","year":"2023","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166135","article-title":"Opportunities for Treg cell therapy for the treatment of human disease","volume":"14","author":"Bluestone","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030483","article-title":"Machine learning methods in clinical flow cytometry","volume":"17","author":"Spies","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105076_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1432816","article-title":"Design and validation of novel flow cytometry panels to analyze a comprehensive range of peripheral immune cells in mice","volume":"15","author":"Barco-Tejada","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105076_bib113","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4103\/jfmpc.jfmpc_2257_22","article-title":"Multi-centric clinic trials in evidence-based research - A narrative review on the Indian scenario","volume":"12","author":"Patil","year":"2023","journal-title":"J. Fam. Med. Prim. Care"},{"key":"10.1016\/j.critrevonc.2025.105076_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1438587","article-title":"Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy","volume":"15","author":"Qin","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12672-025-02064-7","article-title":"AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis","volume":"16","author":"Alum","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib116","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","article-title":"Convergence of evolving artificial intelligence and machine learning techniques in precision oncology","volume":"8","author":"Fountzilas","year":"2025","journal-title":"NPJ Digit Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib117","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1038\/s41467-025-63915-z","article-title":"Integrating cross-sample and cross-modal data for spatial transcriptomics and metabolomics with SpatialMETA","volume":"16","author":"Tian","year":"2025","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105076_bib118","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.ccell.2025.06.020","article-title":"Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105076_bib119","article-title":"Identification of a stromal immunosuppressive barrier orchestrated by SPP1(+)\/C1QC(+) macrophages and CD8(+) exhausted T cells driving gastric cancer immunotherapy resistance","volume":"16","author":"Ma","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105076_bib120","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1053\/j.gastro.2023.05.036","article-title":"Spatially resolved multi-omics single-cell analyses inform mechanisms of immune dysfunction in pancreatic cancer","volume":"165","author":"Yousuf","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2025.105076_bib121","first-page":"511","article-title":"Enhancing early detection of pancreatic cancer in genetically predisposed individuals: integrating advanced imaging modalities with emerging biomarkers and liquid biopsy","volume":"19","author":"Abdel-Razeq","year":"2025","journal-title":"Biologics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib122","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105076_bib123","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cei\/uxac118","article-title":"The potential for Treg-enhancing therapies in transplantation","volume":"211","author":"Steiner","year":"2023","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105076_bib124","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i9.109055","article-title":"Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance","volume":"17","author":"Kim","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343929","article-title":"An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer","volume":"15","author":"Lutz","year":"2024","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105076_bib126","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/0008-5472.CAN-23-2352","article-title":"Multiplexed imaging mass cytometry analysis characterizes the vascular niche in pancreatic cancer","volume":"84","author":"Sussman","year":"2024","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib127","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/s41416-024-02882-6","article-title":"Spatial analysis by current multiplexed imaging technologies for the molecular characterisation of cancer tissues","volume":"131","author":"Semba","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111569","article-title":"CD137 agonism enhances anti-PD1 induced activation of expanded CD8(+) T cell clones in a neoadjuvant pancreatic cancer clinical trial","volume":"28","author":"Montagne","year":"2025","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12935-025-03944-2","article-title":"Integration of multi-omics approaches in exploring intra-tumoral heterogeneity","volume":"25","author":"Dong","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/ph18010075","article-title":"Leveraging single-cell multi-omics to decode tumor microenvironment diversity and therapeutic resistance","volume":"18","author":"Sabit","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib131","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40364-024-00643-4","article-title":"Single-cell sequencing to multi-omics: technologies and applications","volume":"12","author":"Wu","year":"2024","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105076_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26062447","article-title":"Single-cell multi-omics: insights into therapeutic innovations to advance treatment in cancer","volume":"26","author":"Guan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105076_bib133","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s10038-024-01231-y","article-title":"Advances in AI and machine learning for predictive medicine","volume":"69","author":"Sharma","year":"2024","journal-title":"J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib134","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-024-01110-w","article-title":"Unlocking precision medicine: clinical applications of integrating health records, genetics, and immunology through artificial intelligence","volume":"32","author":"Chen","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12967-023-04807-y","article-title":"Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105076_bib136","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/2326-6066.CIR-24-0758","article-title":"IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma","volume":"13","author":"Schmiechen","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib137","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2539442","article-title":"Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8(+) T cell infiltration","volume":"14","author":"Shi","year":"2025","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000651","article-title":"Bias in medical AI: implications for clinical decision-making","volume":"3","author":"Cross","year":"2024","journal-title":"PLOS Digit Health"},{"key":"10.1016\/j.critrevonc.2025.105076_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2024.1430245","article-title":"A review on over-sampling techniques in classification of multi-class imbalanced datasets: insights for medical problems","volume":"6","author":"Yang","year":"2024","journal-title":"Front. Digit Health"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib140","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib141","doi-asserted-by":"crossref","first-page":"413","DOI":"10.11124\/JBIES-23-00078","article-title":"Meta-analysis on studies with heterogeneous and partially observed covariates","volume":"22","author":"Akkaya Hocagil","year":"2024","journal-title":"JBI Evid. Synth."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib142","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41522-025-00819-2","article-title":"Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors","volume":"11","author":"Huang","year":"2025","journal-title":"NPJ Biofilms Micro"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib143","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.105076_bib144","article-title":"Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105076_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166746","article-title":"Targeting the tumor microenvironment: Potential strategy for cancer therapeutics","volume":"1869","author":"Babar","year":"2023","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.critrevonc.2025.105076_bib147","article-title":"Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics","author":"Liu","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105076_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1287077","article-title":"Gut microbiota and its therapeutic implications in tumor microenvironment interactions","volume":"15","author":"Feng","year":"2024","journal-title":"Front. Microbiol"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib149","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s12967-024-05709-3","article-title":"Influence of the gut microbiota on immune cell interactions and cancer treatment","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105076_bib150","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","article-title":"Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"issue":"36","key":"10.1016\/j.critrevonc.2025.105076_bib151","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202500806","article-title":"The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1\/c-MET Signaling in Pancreatic Cancer","volume":"12","author":"Han","year":"2025","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib152","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12911-024-02681-2","article-title":"Decision threshold models in medical decision making: a scoping literature review","volume":"24","author":"Scarffe","year":"2024","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"10.1016\/j.critrevonc.2025.105076_bib153","article-title":"Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy","volume":"13","author":"Hua","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105076_bib154","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041022","article-title":"Challenges and therapeutic opportunities in the dMMR\/MSI-H colorectal cancer landscape","volume":"15","author":"Mulet-Margalef","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105076_bib155","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.98366.3","article-title":"Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer","volume":"13","author":"Kim","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.critrevonc.2025.105076_bib156","article-title":"Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib157","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cytogfr.2024.08.006","article-title":"Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis","volume":"79","author":"Yu","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105076_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179506","article-title":"Lymphocyte T subsets and outcome of immune checkpoint inhibitors in melanoma patients: an oncologist's perspective on current knowledge","volume":"25","author":"Martinez-Vila","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105076_bib159","article-title":"An immune-related gene pair index predicts clinical response and survival outcome of immune checkpoint inhibitors in melanoma","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105076_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/cells13181526","article-title":"Treg cell therapeutic strategies for breast cancer: holistic to local aspects","volume":"13","author":"Zhang","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib161","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13104-024-06704-z","article-title":"The relationship between high ratios of CD4\/FOXP3 and CD8\/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study","volume":"17","author":"Tenggara","year":"2024","journal-title":"BMC Res. Notes"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib162","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54874-y","article-title":"Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling","volume":"15","author":"Piao","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib163","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12967-025-06139-5","article-title":"The clinical application of artificial intelligence in cancer precision treatment","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib164","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","article-title":"Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition","volume":"18","author":"Glaviano","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105076_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383978","article-title":"Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application","volume":"15","author":"Zheng","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib166","article-title":"Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines","volume":"32","author":"Amhis","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105076_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030332","article-title":"Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare","volume":"16","author":"Marques","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105076_bib168","first-page":"33","article-title":"Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization","volume":"22","author":"Chang","year":"2025","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105076_bib169","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/cas.16097","article-title":"Beyond blood: advancing the frontiers of liquid biopsy in oncology and personalized medicine","volume":"115","author":"Bao","year":"2024","journal-title":"Cancer Sci."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105076_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13206036","article-title":"From bench to bedside: a team's approach to multidisciplinary strategies to combat therapeutic resistance in head and neck squamous cell carcinoma","volume":"13","author":"Crossman","year":"2024","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105076_bib171","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009721","article-title":"Ten challenges and opportunities in computational immuno-oncology","volume":"12","author":"Bao","year":"2024","journal-title":"J. Immunother. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:52:10Z","timestamp":1773093130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":171,"alternative-id":["S1040842825004640"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105076","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the effector-to-regulatory T cell ratio to advance prognosis and precision therapy in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105076"}}